(1): Carbon Spectrum
(2): Hydrogen Spectrum
Pharmacology and Pharmacokinetics
The chemical structure of lenalidomide
is similar to thalidomide. Although the exact mechanism of lenalidomide is not yet clear, it has been known that lenalidomide has functions of immunomodulation and anti neovascularization. After taking this medicine, lenalidomide is quickly absorbed into the body. In vitro experiments show that the plasma protein binding rate of lenalidomide was about 30%. Approximately 2/3 of lenalidomide is excreted in the original form with urine, and its eliminating half-life is about 3 hours.
This product is used with dexamethasone to treat adult patients with multiple myeloma who have received at least one treatment.
Usage and Dosage
It is necessary to start therapeutic medication under the supervision of doctors who have multiple myeloma treatment experience.
If the absolute count of neutrophils (ANC) is < 1.0 x 109 /L, or the patient's platelet count is < 50 x 109 /L, and the proportion of the plasma cell in the bone marrow is < 50%, or the patient's platelet count < 30 x 109 /L, and the proportion of the plasma cell in the bone marrow of the nucleus cells is > 50%, it should not be treated with this product.
The recommended initial dose of this product is 25mg. On the 1~21 day of each repeated 28 day cycle, take 25 mg of the product daily until the disease progresses. The recommended dose of dexamethasone was oral it on the first, the eighth, the fifteenth and the twenty-sedond days of treatment during every 28 day cycle. The prescription doctor should carefully select the initial dose and adjust subsequent dose according to the patient's renal function. The initial dose of dexamethasone should be selected according to the patient's age and the subsequent dose should be adjusted.